Source: International Congress 2017 – PAH and CTEPH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Gavilanes Oleas (Sao Paulo/Sp, Brazil). The use of new anticoagulants in CTEPH. 2409

Member's Comments

No comment yet.

Related content which might interest you: Treatment of CTEPH and anticoagulation of choice Source: ERS Course 2019 - Masterclass in pulmonary embolism Year: 2019 Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Anticoagulant treatment of venous thromboembolism: established and new oral agents, remaining questions Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014 Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures Source: Eur Respir Rev, 26 (145) 170020; 10.1183/16000617.0020-2017 Year: 2017 Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension Year: 2019 Combining therapeutical options in CTEPH Source: International Congress 2018 – CC2 Broad spectrum of chronic thromboembolic pulmonary hypertension Year: 2018 Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Effectiveness of thrombolytic therapy in pulmonary thromboembolism Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 The changing of D-dimer in the thrombolytic process of pulmonary thromboembolism Source: Eur Respir J 2006; 28: Suppl. 50, 401s Year: 2006 Prospects for the prevention and treatment of venous thromboembolism Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=155 Year: 2004 Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension Source: Eur Respir J 2013; 41: 872-878 Year: 2013 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Efficacy and safety of treatment with anticoagulants in patients with unprovoked venous thromboembolism in Korea Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach Source: Eur Respir J 2015; 45: 1142-1149 Year: 2015 Complications of anticoagulant therapy in patients with pulmonary thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 604s Year: 2007 Comparison of two regimens of oral anticoagulation in pulmonary embolism Source: Eur Respir J 2006; 28: Suppl. 50, 632s Year: 2006 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 How to treat CTEPH Source: International Congress 2017 – From acute clots to chronic thromboembolic pulmonary hypertension Year: 2017 Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012